The Catalonia Suicide Risk Code Epidemiology Study: an Epidemiological Study of Suicide Attempts in Catalonia, Spain
NCT ID: NCT04235127
Last Updated: 2020-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
186000 participants
OBSERVATIONAL
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging
NCT02889042
Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
NCT00218725
Study of Addiction Criteria in the Elderly
NCT03509077
A Randomized Clinical Study of "Attempted Suicide Short Intervention Program" in Swedish Healthcare - ASSIP
NCT04746261
Facilitating Use of the National Suicide Prevention Lifeline in Alcohol Patients (Reach Out)
NCT04488055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Catalan population
The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being \~2.5%, \~1.9%, \~0.9%, and \~0.8%, respectively. Based on these figures, we expect a maximum of \~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., \~10.9%), lowering the total expected target population to \~8.1 million.
sociodemographic variables, somatic conditions, mental disorders, treatment and drug use
* sociodemographic variables
* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.
* prescriptions for psychopharmacological products
* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sociodemographic variables, somatic conditions, mental disorders, treatment and drug use
* sociodemographic variables
* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.
* prescriptions for psychopharmacological products
* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 10 or more at end of observation period
Exclusion Criteria
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catalan Agency for Health Information, Assessment and Quality
OTHER_GOV
National Centre for Suicide Research and Prevention, Norway
UNKNOWN
Harvard Medical School (HMS and HSDM)
OTHER
Hospital del Mar Research Institute (IMIM)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jordi Alonso
M.D., Ph.D., Coordinator of the Health Services Research Group, Director of the Epidemiology and Public Health Program
References
Explore related publications, articles, or registry entries linked to this study.
Mortier P, Vilagut G, Puertolas Gracia B, De Ines Trujillo A, Alayo Bueno I, Ballester Coma L, Blasco Cubedo MJ, Cardoner N, Colls C, Elices M, Garcia-Altes A, Gene Badia M, Gomez Sanchez J, Martin Sanchez M, Morros R, Prat Pubill B, Qin P, Mehlum L, Kessler RC, Palao D, Perez Sola V, Alonso J; CODIRISC Epidemiology Study Group. Catalonia Suicide Risk Code Epidemiology (CSRC-Epi) study: protocol for a population-representative nested case-control study of suicide attempts in Catalonia, Spain. BMJ Open. 2020 Jul 12;10(7):e037365. doi: 10.1136/bmjopen-2020-037365.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSRC-EPI (2017/7431/I)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.